Teresa Jurgensen, J.D.

Executive Vice President, General Counsel

Teresa Jurgensen has spent the last two decades working in the biotech, pharmaceutical and life sciences industries as a business partner and lawyer. Teresa was most recently the SVP, general counsel and head of enabling functions at 2seventy bio, a spin-out of bluebird bio where Teresa led the legal, IT and facilities teams. As general counsel, Teresa was responsible for executing on 2seventy’s key strategic transactions, including equity financings, and most recently the divestiture of its pipeline programs to Regeneron. At bluebird bio Teresa served as the general counsel of its oncology business. Prior to 2seventy bio/bluebird, Teresa was associate general counsel at Teva Pharmaceuticals where, notably, she led the divestiture of Teva’s women’s health business, and other key strategic transactions. Teresa holds a B.S. from Penn State University and a J.D. from Widener University School of Law.